Year: 2021

VANCOUVER, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) — West Mining Corp. (“West” or the “Company”) (CSE: WEST) (OTC: WESMF) is pleased to report the completion of an initial 7 diamond drill holes on the Kena Copper Zone area of its 100% owned Kena gold and copper project in southeastern British Columbia. All of the holes intercepted strong zones of alteration and silicification along with variable pyrite-chalcopyrite mineralization throughout. The Kena Copper Zone is identified by a significant copper geochemical anomaly associated with a strong zone of high chargeability, lying within mafic volcanic and subvolcanic diorites of the Rossland Group Elise Formation. The soil anomaly has dimensions of 2.5 kilometres in length by an average of 450 metres in width as outlined by the 300 ppm copper contour. Within the anomaly there...

DENVER and VANCOUVER, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) — SPOTLITE360 IOT SOLUTIONS, INC. (“SpotLite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) is pleased to announce that it has been contracted by E3 Service Group LLC (“E3”) to provide professional services relating to the development and integration of technologies including Internet-of-Things (“IoT”) sensors as well as corresponding software applications to gather and leverage data collected on a continuous basis. Established in 2012, E3 develops, designs, and builds cannabis cultivation facilities with a focus on optimally configuring heating, ventilation, and air conditioning (“HVAC”) infrastructure to create an ideal environment for growing cannabis plants. E3’s primary business objective in working with SpotLite360 is to harvest a wide...

Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly specific RNA editing and restoration of functional AAT protein substantially above therapeutic threshold; potential for best-in-class, potent and durable RNA editing in vivo in multiple preclinical models and tissues Dosing ongoing in three clinical programs (WVE-004, WVE-003, WVE-N531); data being generated through 2022 to enable decision-making Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases,...

DENVER, Nov. 10, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that Dr. Rakesh Jetly, Chief Medical Officer of Mydecine, will be participating in a panel entitled, “The State of Care and the Case for Psychedelic Therapy” on Wednesday, November 10, 2021 at 7:30 p.m. on the eve of Veterans Day also known as Remembrance Day in Canada. Hosted by Reconsider and Horizons PBC, the first of their events specifically for the veterans community, will take place live in NYC at Judson Memorial Church and will be available virtually worldwide. The Veterans + Families Forum explores the potential of therapies that use MDMA, psilocybin,...

Announces Intent to Develop TSC to Treat Hypoxic Tumors Altitude Trial Expected to Commence in November 2021 ILD-DLCO Trial Expected to Commence in Late December 2021CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the third quarter of 2021 and provided a business update. “We believe this is an exciting time for Diffusion Pharmaceuticals. The data we have obtained over the last year from our TCOM and COVID-19 studies have enhanced our understanding of TSC dosing and its mechanism of action, which we feel provides support for the broad potential use of TSC as a treatment...

Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate   Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent manner up to 72 weeks in patients with IgA nephropathy   Vera reported approximately $86.2 million in cash and cash equivalents as of September 30, 2021SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, today reported its business highlights and financial results for the quarter ending September 30, 2021, and provided a corporate update. “Vera’s third-quarter...

Retailers & Brands Get Audience Measurement, Content Management & Increased Sales Lift from Engagement with Customers Directly at Point of Sale Philadelphia, PA, Nov. 10, 2021 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (OTCQB: VSBGF) (CSE: VSBY) (Frankfurt 5VS) (“VSBLTY”), a leading software provider of security and retail analytics technology, today announced that it has signed a letter of intent with Phoenix Vision to collaborate on building a major media network starting with more than 600 convenience stores throughout the U.S. VSBLTY’s other global ecosystem partners will be providing turnkey services from the acquisition of hardware through deployment of the network, analytics reporting and field maintenance support, according to the announcement. Las Vegas-based Phoenix Vision now offers digital displays...

Serstech’s long-standing vision is to connect multiple products and technologies into solutions that can solve a larger part of the customer problems. Today, Serstech signs a collaboration agreement with British manufacturer 3DX-Ray, a global market and technology leader in x-ray imaging systems for security and industrial applications. Sales and marketing efforts of the joint solution will begin immediately. Serstech’s Raman instruments are excellent at identifying hazardous substances, but the laws of physics prevent Raman technology from detecting substances inside bags, freight containers and other non-transparent materials. X-Ray machines cannot identify a substance but can detect the presence of suspicious content inside virtually all types of containers. The combination of x-ray and Raman can both detect and identify suspicious...

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced financial results for the third quarter ended September 30, 2021. Recent Business HighlightsBooked orders of $137.4 million year-to-date resulting in backlog of $151.8 million, as of November 10, 2021 $3.4 million in product shipped, as of November 10, 2021 Substantial improvement in manufacturing quality and yields; continue to affirm our model to achieve high scalability, low ramp lead time and low investment materiality risk vs. alternate storage technologies On October 5, 2021, Eos announced a $25 million equipment financing agreement with Trinity Capital to enhance manufacturing operations and further...

New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks New data presented at ACG annual meeting from PRISM3 Phase 2 trial of CP101 in recurrent CDI show a statistically significant improvement in sustained clinical cure and a safety profile similar to placebo through 24 weeks Initiated enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI Continued progress advancing platform and development programs, with construction completed on new manufacturing facility and two programs positioned to enter the clinic in 2022SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH),...